Rheumatoid arthritis is a chronic inflammatory disease that affects the joints, causing pain and swelling. It is an autoimmune disorder that causes the body to attack its own tissues. The most common symptoms of rheumatoid arthritis are joint pain, stiffness, and swelling. Other symptoms include fatigue, morning stiffness, joint redness or warmth, and decreased range of motion in the affected joints. Prescription drugs are used to treat rheumatoid arthritis by reducing inflammation in the body and relieving pain. Ovethcounter drugs are used for relief from milder forms of rheumatoid arthritis such as osteoarthritis or other types of inflammatory conditions such as psoriasis or lupus erythematosus. Prescription drugs include methotrexate (MTX), leflunomide (Arava), hydroxychloroquine sulfate (Plaquenil), sulfasalazine (Azulfidine) and etanercept (Enbrel). Ovethcounter drugs include ibuprofen (Advil) and naproxen sodium (Aleve).
- The global Rheumatoid Arthritis Drugs market is expected to grow at a CAGR of 4.5% from 2017 to 2022.
- Increasing prevalence of chronic diseases such as arthritis and diabetes is expected to drive the growth of the global Rheumatoid Arthritis Drugs market over the forecast period.
- The increasing number of patients with rheumatoid arthritis is also expected to fuel the growth of this market over the forecast period.
- Increasing awareness about various treatment options for rheumatoid arthritis and rising disposable income are also anticipated to drive demand for these drugs in emerging economies such as China and India over the next few years, thereby propelling their growth in this region during this time span.
Industry Growth Insights published a new data on “Rheumatoid Arthritis Drugs Market”. The research report is titled “Rheumatoid Arthritis Drugs Market research by Types (Prescription Drugs, Over-the-counter Drugs), By Applications (Hospital, Clinic, Nursing home, Other), By Players/Companies AbbVie, Amgen, Bayer, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, F. Hoffmann-La Roche, Johnson and Johnson, Merck, Mitsubishi Tanabe Pharma, Novartis, Pfizer, UCB S.A”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Rheumatoid Arthritis Drugs Market Research Report
By Type
Prescription Drugs, Over-the-counter Drugs
By Application
Hospital, Clinic, Nursing home, Other
By Companies
AbbVie, Amgen, Bayer, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, F. Hoffmann-La Roche, Johnson and Johnson, Merck, Mitsubishi Tanabe Pharma, Novartis, Pfizer, UCB S.A
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
246
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Rheumatoid Arthritis Drugs Market Report Segments:
The global Rheumatoid Arthritis Drugs market is segmented on the basis of:
Types
Prescription Drugs, Over-the-counter Drugs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Nursing home, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AbbVie
- Amgen
- Bayer
- Biogen
- Boehringer Ingelheim
- Bristol-Myers Squibb
- F. Hoffmann-La Roche
- Johnson and Johnson
- Merck
- Mitsubishi Tanabe Pharma
- Novartis
- Pfizer
- UCB S.A
Highlights of The Rheumatoid Arthritis Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Prescription Drugs
- Over-the-counter Drugs
- By Application:
- Hospital
- Clinic
- Nursing home
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Rheumatoid Arthritis Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Rheumatoid arthritis drugs are medications that help to relieve the symptoms of rheumatoid arthritis. These medications can include anti-inflammatory drugs, painkillers, and disease-modifying antirheumatic drugs (DMARDs).
Some of the major players in the rheumatoid arthritis drugs market are AbbVie, Amgen, Bayer, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, F. Hoffmann-La Roche, Johnson and Johnson, Merck, Mitsubishi Tanabe Pharma, Novartis, Pfizer, UCB S.A.
The rheumatoid arthritis drugs market is expected to register a CAGR of 4.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Rheumatoid Arthritis Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Rheumatoid Arthritis Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Rheumatoid Arthritis Drugs Market - Supply Chain
4.5. Global Rheumatoid Arthritis Drugs Market Forecast
4.5.1. Rheumatoid Arthritis Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Rheumatoid Arthritis Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Rheumatoid Arthritis Drugs Market Absolute $ Opportunity
5. Global Rheumatoid Arthritis Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Rheumatoid Arthritis Drugs Market Size and Volume Forecast by Type
5.3.1. Prescription Drugs
5.3.2. Over-the-counter Drugs
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Rheumatoid Arthritis Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Rheumatoid Arthritis Drugs Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinic
6.3.3. Nursing home
6.3.4. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Rheumatoid Arthritis Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Rheumatoid Arthritis Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Rheumatoid Arthritis Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Rheumatoid Arthritis Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Rheumatoid Arthritis Drugs Demand Share Forecast, 2019-2026
9. North America Rheumatoid Arthritis Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Rheumatoid Arthritis Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Rheumatoid Arthritis Drugs Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinic
9.4.3. Nursing home
9.4.4. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Rheumatoid Arthritis Drugs Market Size and Volume Forecast by Type
9.7.1. Prescription Drugs
9.7.2. Over-the-counter Drugs
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Rheumatoid Arthritis Drugs Demand Share Forecast, 2019-2026
10. Latin America Rheumatoid Arthritis Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Rheumatoid Arthritis Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Rheumatoid Arthritis Drugs Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinic
10.4.3. Nursing home
10.4.4. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Rheumatoid Arthritis Drugs Market Size and Volume Forecast by Type
10.7.1. Prescription Drugs
10.7.2. Over-the-counter Drugs
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Rheumatoid Arthritis Drugs Demand Share Forecast, 2019-2026
11. Europe Rheumatoid Arthritis Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Rheumatoid Arthritis Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Rheumatoid Arthritis Drugs Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinic
11.4.3. Nursing home
11.4.4. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Rheumatoid Arthritis Drugs Market Size and Volume Forecast by Type
11.7.1. Prescription Drugs
11.7.2. Over-the-counter Drugs
11.8. Basis Point Share (BPS) nalysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Rheumatoid Arthritis Drugs Demand Share, 2019-2026
12. Asia Pacific Rheumatoid Arthritis Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Rheumatoid Arthritis Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Rheumatoid Arthritis Drugs Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinic
12.4.3. Nursing home
12.4.4. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Rheumatoid Arthritis Drugs Market Size and Volume Forecast by Type
12.7.1. Prescription Drugs
12.7.2. Over-the-counter Drugs
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Rheumatoid Arthritis Drugs Demand Share, 2019-2026
13. Middle East & Africa Rheumatoid Arthritis Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Rheumatoid Arthritis Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Rheumatoid Arthritis Drugs Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinic
13.4.3. Nursing home
13.4.4. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Rheumatoid Arthritis Drugs Market Size and Volume Forecast by Type
13.7.1. Prescription Drugs
13.7.2. Over-the-counter Drugs
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Rheumatoid Arthritis Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Rheumatoid Arthritis Drugs Market: Market Share Analysis
14.2. Rheumatoid Arthritis Drugs Distributors and Customers
14.3. Rheumatoid Arthritis Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. AbbVie
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Amgen
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Bayer
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Biogen
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Boehringer Ingelheim
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Bristol-Myers Squibb
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. F. Hoffmann-La Roche
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Johnson and Johnson
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Merck
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Mitsubishi Tanabe Pharma
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Novartis
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Pfizer
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. UCB S.A
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook